Blueprint Medicines (BPMC) News Today → I’m afraid WWIII is a very real possibility (From Porter & Company) (Ad) Free BPMC Stock Alerts $104.96 -1.68 (-1.58%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 5:32 AM | americanbankingnews.comBlueprint Medicines Co. (NASDAQ:BPMC) Short Interest Up 6.8% in AprilMay 17 at 2:34 AM | americanbankingnews.comAnalysts Issue Forecasts for Blueprint Medicines Co.'s Q2 2024 Earnings (NASDAQ:BPMC)May 16 at 2:56 PM | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Short Interest UpdateBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) was the recipient of a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 4,540,000 shares, an increase of 6.8% from the April 15th total of 4,250,000 shares. Based on an average daily volume of 830,500 shares, the short-interest ratio is presently 5.5 days.May 16 at 7:51 AM | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Forecasted to Post Q2 2024 Earnings of ($1.40) Per ShareBlueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Analysts at Zacks Research issued their Q2 2024 earnings per share estimates for shares of Blueprint Medicines in a note issued to investors on Tuesday, May 14th. Zacks Research analyst A. Chakraborty anticipates that the biotechnology companyMay 15 at 8:23 AM | msn.comStephens & Co. Initiates Coverage of Blueprint Medicines (BPMC) with Overweight RecommendationMay 15 at 6:21 AM | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) Receives New Coverage from Analysts at StephensMay 14, 2024 | msn.comBlueprint Medicines started at buy by Stephens, citing Ayvakit franchiseMay 14, 2024 | markets.businessinsider.comUnveiling 18 Analyst Insights On Blueprint MedicinesMay 14, 2024 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Hits New 1-Year High at $111.02Blueprint Medicines (NASDAQ:BPMC) Sets New 52-Week High at $111.02May 14, 2024 | marketbeat.comStephens Initiates Coverage on Blueprint Medicines (NASDAQ:BPMC)Stephens began coverage on Blueprint Medicines in a research report on Tuesday. They set an "overweight" rating and a $140.00 target price on the stock.May 13, 2024 | marketbeat.comSwiss National Bank Sells 19,400 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Swiss National Bank decreased its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 14.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 113,500 shares of the biotechnologyMay 12, 2024 | marketbeat.comVictory Capital Management Inc. Grows Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)Victory Capital Management Inc. increased its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 1,906.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 131,050 shares of the biotechnology company's stock after bMay 9, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)May 9, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for Blueprint Medicines Co. Issued By Leerink Partnrs (NASDAQ:BPMC)May 8, 2024 | marketbeat.comBlueprint Medicines Co. Forecasted to Earn Q2 2024 Earnings of ($1.10) Per Share (NASDAQ:BPMC)Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Analysts at Leerink Partnrs issued their Q2 2024 EPS estimates for Blueprint Medicines in a research note issued to investors on Monday, May 6th. Leerink Partnrs analyst A. Berens anticipates that the biotechnology company will earn ($1.10) peMay 8, 2024 | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) PT Raised to $168.00 at The Goldman Sachs GroupMay 8, 2024 | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) Rating Increased to Market Perform at SVB LeerinkMay 7, 2024 | finance.yahoo.comZacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and LigandMay 7, 2024 | insidertrades.comAriel Hurley Sells 1,834 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) StockMay 7, 2024 | insidertrades.comMichael Landsittel Sells 10,000 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) StockMay 7, 2024 | msn.comLeerink Partners Upgrades Blueprint Medicines (BPMC)May 6, 2024 | prnewswire.comBlueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 6, 2024 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Upgraded at SVB LeerinkSVB Leerink raised shares of Blueprint Medicines from an "underperform" rating to a "market perform" rating and boosted their price target for the stock from $50.00 to $97.00 in a research note on Monday.May 5, 2024 | marketbeat.comFisher Asset Management LLC Has $30.12 Million Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)Fisher Asset Management LLC trimmed its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 14.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 326,564 shares of the biotechnology compaMay 4, 2024 | markets.businessinsider.comSell/High Risk: Cautious Outlook on Blueprint Medicines Amidst Unsustainable Growth FactorsMay 4, 2024 | finance.yahoo.comBlueprint Medicines Corp (BPMC) (Q1 2024) Earnings Call Transcript Highlights: Surpassing ...May 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Blueprint Medicines on Strong Financials and Clinical Pipeline ProspectsMay 4, 2024 | finance.yahoo.comBlueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Raised to Hold at StockNews.comStockNews.com upgraded shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a research note on Friday.May 3, 2024 | marketbeat.comCitigroup Raises Blueprint Medicines (NASDAQ:BPMC) Price Target to $76.00Citigroup upped their target price on shares of Blueprint Medicines from $65.00 to $76.00 and gave the stock a "sell" rating in a research report on Friday.May 3, 2024 | finance.yahoo.comQ1 2024 Blueprint Medicines Corp Earnings CallMay 2, 2024 | marketwatch.comBlueprint Medicines Shares Hit 52-Week on Strong Ayvakit SalesMay 2, 2024 | msn.comBPMC Stock Earnings: Blueprint Medicines Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | finance.yahoo.comBlueprint Medicines Corp Reports Q1 2024 Earnings, Surpasses Revenue Estimates and Raises ...May 2, 2024 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Hits New 52-Week High at $107.56Blueprint Medicines (NASDAQ:BPMC) Reaches New 1-Year High at $107.56May 2, 2024 | seekingalpha.comBlueprint Medicines Corporation 2024 Q1 - Results - Earnings Call PresentationMay 2, 2024 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Stock Rating Reaffirmed by Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $97.00 price target on shares of Blueprint Medicines in a research report on Thursday.May 2, 2024 | prnewswire.comBlueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceApril 30, 2024 | marketbeat.comJackson Creek Investment Advisors LLC Purchases New Stake in Blueprint Medicines Co. (NASDAQ:BPMC)Jackson Creek Investment Advisors LLC purchased a new stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,498 shares of the biotechnolApril 30, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Receives Average Recommendation of "Moderate Buy" from AnalystsBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fourteen ratings firms that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rApril 29, 2024 | seekingalpha.comRigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A BuyApril 29, 2024 | marketbeat.comFederated Hermes Inc. Buys Shares of 24,043 Blueprint Medicines Co. (NASDAQ:BPMC)Federated Hermes Inc. bought a new stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 24,043 shares of the biotechnology company's stock, valued at approximatelApril 27, 2024 | marketbeat.comState of New Jersey Common Pension Fund D Sells 13,058 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)State of New Jersey Common Pension Fund D cut its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 25.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,619 shares of the biotechnology company's stock aftApril 26, 2024 | finance.yahoo.comRubrik to debut on NYSE, IPO priced at $32 per shareApril 26, 2024 | marketbeat.comStifel Nicolaus Increases Blueprint Medicines (NASDAQ:BPMC) Price Target to $130.00Stifel Nicolaus boosted their target price on Blueprint Medicines from $120.00 to $130.00 and gave the company a "buy" rating in a report on Friday.April 26, 2024 | marketbeat.comBlueprint Medicines' (BPMC) "Outperform" Rating Reiterated at WedbushWedbush reaffirmed an "outperform" rating and set a $110.00 price objective on shares of Blueprint Medicines in a research report on Friday.April 26, 2024 | markets.businessinsider.comBlueprint Medicines Corporation: A Strong Buy on Robust Pipeline and Market Potential for Mast Cell Disease TreatmentsApril 26, 2024 | markets.businessinsider.comThe Analyst Verdict: Blueprint Medicines In The Eyes Of 7 ExpertsApril 25, 2024 | marketbeat.comSemanteon Capital Management LP Makes New $1.18 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC)Semanteon Capital Management LP purchased a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 12,758 shares of the biotechnology company's stock, valued at approxiApril 24, 2024 | marketbeat.comBlueprint Medicines (BPMC) to Release Quarterly Earnings on ThursdayBlueprint Medicines (NASDAQ:BPMC) will be releasing earnings before the market opens on Thursday, April 25, Yahoo Finance reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=586367) Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address I’m afraid WWIII is a very real possibility (Ad)As one top U.S. cyber official claims: This [tech] is “the most powerful weapon of our time.” That's also why I've produced this new film. Take a look. BPMC Media Mentions By Week BPMC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BPMC News Sentiment▼0.690.50▲Average Medical News Sentiment BPMC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BPMC Articles This Week▼176▲BPMC Articles Average Week Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CYTK News Today ITCI News Today JAZZ News Today ASND News Today IONS News Today OGN News Today BBIO News Today CERE News Today APLS News Today VKTX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BPMC) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA once-in-a-century investment opportunityStansberry ResearchMost important medical advance in 100 yearsThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
